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What’s new? 
 Hyperglycaemia during chemotherapy treatment is associated with negative health outcomes. 
 The incidence, severity and diurnal profile of glucose dysregulation during chemotherapy are 
unclear, limiting development of screening and treatment protocols. 
 Utilizing continuous glucose monitoring, these data demonstrate that elevated glucose levels 
affect nearly all women treated with a standard carboplatin/paclitaxel/dexamethasone 
chemotherapeutic regimen for gynaecological cancer. 
 The diurnal profile is described with peak glucose windows for opportunistic monitoring. 
  HbA1c was independently associated with the severity and duration of glucose excursions. 
 
Abstract 
Aims Hyperglycaemia, a side-effect of acute glucocorticoid exposure, is associated with poor 
outcome in those undergoing chemotherapy. The incidence, risk factors and diurnal profile of 












This article is protected by copyright. All rights reserved. 
 
Methods Blinded continuous interstitial glucose monitoring was performed on 16 women without 
diabetes for 24 h prior to and 5 days following carboplatin/paclitaxel chemotherapy combined with 
dexamethasone treatment for gynaecological cancer. At the end of the treatment period, glucose 
data were analysed and integrated with baseline metabolic and anthropomorphic variables. 
 
Results Some 15/16 (94%) women exhibited elevated glucose levels (> 11.1 mmol/l). Peak glucose 
levels were highest on the day of treatment (median 14.45 mmol/l, range 10.2–22.2 mmol/l) and 
total time spent with an elevated interstitial glucose level was highly variable (median 3.6 h, range 
0.0–55.1 h). Peak interstitial glucose levels occurred predominantly, but not exclusively, in the 
afternoon (13.00–15.00) and evening (19.00–22.00); however, elevated levels were noted 
throughout the 24-h period. Baseline HbA1c was independently associated with severity and duration 
of elevated glucose levels in a regression adjusted for baseline BMI. 
 
Conclusions These data report for the first time that high glucose levels are encountered by nearly 
all women following this regimen, the severity and duration of which are independently associated 




Glucocorticoids are anti-inflammatory and immunomodulatory medications widely employed in the 
treatment of inflammatory and neoplastic conditions [1]. In the context of taxane- and platinum salt-
based chemotherapy, dexamethasone is effective in reducing hypersensitivity reactions and delayed 
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However, hyperglycaemia is a common and unwanted side-effect of supraphysiological, acute 
glucocorticoid therapy. Mechanistically, this is driven by impaired insulin action and peripheral 
glucose uptake in addition to suppression of pancreatic -cell function [3,4]. Both Type 1 and Type 2 
diabetes mellitus are associated with negative health outcomes in cancer treatment, including an 
increased incidence of bacteraemia, a higher incidence of drug toxicity and increased all-cause 
mortality [5–7]. Specifically, in gynaecological cancer, impaired fasting glucose was associated with a 
significant reduction in disease-free survival even at a modest threshold of 5.5 mmol/l [8–10]. The 
reason for this observation is unclear and may not be due to hyperglycaemia per se. Possible 
explanations include the association of diabetes with micro- and macrovascular disease or the 
presence of hyperinsulinemia. However, pre-clinical in vitro studies suggest that hyperglycaemia 
attenuates the efficacy of chemotherapeutic agents on the majority of cancer cell lines, including 
ovarian tumour cells, by a variety of mechanisms including modification of apoptotic and cell 
proliferation signalling [11]. In human samples, upregulation of the GLUT1 transmembrane glucose 
transporter is an indicator of ovarian neoplastic transformation and an independent predictor of 
poor prognostic outcome [12,13]. Together, these studies suggest that hyperglycaemia may have an 
independent effect on treatment outcome although human data supporting this are lacking. 
 
Despite these observations, the true diurnal glucose profile of people treated with high-dose 
dexamethasone as part of an outpatient chemotherapy regimen is unknown because previous 
studies have typically utilized finger-prick capillary glucose testing four to six times daily, generating 
a limited picture of blood glucose variability throughout an extended treatment period. To address 
this, we performed blinded continuous interstitial glucose monitoring (CGM) on a cohort of 16 
women undergoing carboplatin/paclitaxel chemotherapy combined with high-dose dexamethasone 
treatment for gynaecological cancer in the outpatient setting. CGM measures the glucose 
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surface. In this way, CGM allows estimation of serum glucose levels over long periods and in this 
context such information may significantly inform the development of current guidelines on the 
screening and management of steroid-induced hyperglycaemia [14,15]. 
 
<H1>Participants and methods 
Sixteen women with confirmed gynaecological cancer were recruited into the study at the point of 
referral for combined carboplatin and paclitaxel outpatient chemotherapy treatment (carboplatin 
AUC = 6 mg/h/l, paclitaxel 175 mg/m2) between 2013 and 2015. Women with a WHO performance 
status > 2 or recent (1 month) history of glucocorticoid use were excluded. Baseline 
anthropomorphic variables and family history were recorded, and blood drawn for measurement of 
HbA1c. The day before chemotherapy/dexamethasone treatment (day 0), women were fitted with a 
Medtronic iPRO2™ CGM device (Medtronic, Northridge, CA, USA). On the day of chemotherapy (day 
1), women were treated with high-dose dexamethasone (20 mg at 04.00 and 10 mg at 10.00) 
followed by 4 mg twice daily (08.00 and 12.00) for three subsequent days (days 2–4). Blinded 
interstitial glucose measurements were recorded at 5-min intervals from day 0 to day 5 inclusive and 
were analysed at the end of the study period. The time course of treatment and glucose 
observations is depicted in Fig. 1. An interstitial glucose level of 11.1 mmol/l was chosen as a ceiling 
threshold in this study because it is a level women without diabetes would be unlikely to display on 
a standard day. The study was approved by the National Health Service (NHS) Lothian research 
ethics committee and all women gave written informed consent. CGM devices were calibrated four 
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<H2>Participant characteristics 
Of sixteen women, one discontinued CGM after 3 days (completing days 0, 1 and 2) and these data 
are included in the final analysis. A total of 93 CGM days were analysed, totalling 23 653 individual 
interstitial glucose readings. Baseline characteristics of the women in the study included are in Table 
1. Mean age was 60.1 years (SD ± 8.8) with a mean BMI of 29.1 kg/m2 (SD ± 5.4). All but one woman 
had a diagnosis of ovarian cancer; the remaining woman had endometrial cancer. None had a 
diagnosis of diabetes mellitus or a history of gestational diabetes mellitus. Baseline HbA1c 
concentration was beneath the WHO diagnostic criterion for diabetes (HbA1c ≥ 48 mmol/mol; 6.5%) 
in all women; one had an HbA1c of 44 mmol/mol (6.2%), which met WHO diagnostic criterion for pre-
diabetes (HbA1c 42–47 mmol/mol, 6.1–6.5%). 
 
<H2>Statistical analysis 
Raw data were uploaded and processed in R version 3.2.2 (https://www.r-project.org/). Meaningful 
visualization of the CGM data and comparison between women was challenging due to marked 
variation in mealtimes and activity levels with subsequent temporal variation in interstitial glucose 
excursions. Heat mapping is a method of visualizing data, whereby individual values are represented 
as points on a colour spectrum. This method was employed to depict the diurnal variation in 
interstitial glucose levels throughout the study period using the heatmap.2 function in gplots for R 
(www.cran.r-project.org/web/packages/gplots). To identify independent associates of severity and 
duration of glucose excursions on each day of CGM analysis, lme4 package (https://cran.r-
project.org/web/packages/lme4/index.html) in R was used to create mixed-effects linear models. 
The outcomes ‘peak daily interstitial glucose’ and ‘duration of raised interstitial glucose’ were each 
individually modelled against HbA1c and BMI with the inclusion of individual women and treatment 
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Raised interstitial glucose was virtually ubiquitous among women receiving dexamethasone in 
combination with carboplatin and paclitaxel chemotherapy. Some 15 of 16 (94%) women exhibited 
raised interstitial glucose (> 11.1 mmol/l) on day 1 of the treatment protocol, following the highest 
dose of dexamethasone (30 mg total dose). On day 5, 24 h following the cessation of 
dexamethasone, only 2 of 15 women (13%) continued to demonstrate elevated interstitial glucose 
(Fig. 2). Peak interstitial glucose levels were highest on day 1 of treatment with a median peak 
glucose achieved of 14.5 mmol/l (range 10.2–22.2 mmol/l). On day 5, median peak interstitial 
glucose was 8.8 mmol/l (range 6.7–17.5) mmol/l. 
 
The burden of raised interstitial glucose, as determined by time spent ≥ 11.1 mmol/l, also varied 
considerably (Fig. 3). Time spent in the raised glucose range was greatest on day 1 of treatment 
(median 2.75 h, range 0.00–9.95 h) and lowest on day 5 (median 0.0 h, range 0.00–7.95 h). Total 
time spent within the raised glucose range over the CGM monitoring period following the initiation 
of glucocorticoid therapy was equally variable (median 3.6 h, range 0.0–55.1 h). 
 
<H2>Characterization of the interstitial glucose diurnal rhythm 
Visualization by heat map demonstrated that raised interstitial glucose was typically greatest in the 
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levels of > 11.1 mmol/l were noted in the majority of women throughout the night on each 
treatment day until the morning of day 5, and daily peak glucose levels for many women in the study 
occurred after midnight (00.00– 03.00) on days 2, 3 and 4 of the monitoring period. This suggests 
that dysglycaemia as a consequence of twice-daily dexamethasone treatment (08.00 and 12.00) 
continues over the 24-h period. 
 
<H2>Effect of baseline HbA1c 
Baseline HbA1c was independently associated with peak level of interstitial glucose and the duration 
of raised interstitial glucose. The linear mixed model regression analysis took into account the fact 
that glucose levels were measured in each woman on five separate days of the same steroid 
treatment protocol. This revealed that baseline HbA1c was independently associated with both 
severity of hyperglycaemia, as measured by peak glucose level (slope coefficient = 0.53, P = 0.01), 
and duration of glucose excursions (slope coefficient = 0.43, P = 0.03) in a regression adjusted for 
BMI. As, such the estimated increase in peak glucose level was 0.53 mmol/l and duration of glucose 
excursions was 0.43 h for each mmol/mol increase in HbA1c (Table S1). 
 
One woman in the study had an HbA1c in the pre-diabetes range (44 mmol/mol; 6.2%). She was 
noted to have a considerably greater severity and duration of raised interstitial glucose on each day 
of the study, spending 55 h with an interstitial glucose > 11.1 mmol/l with a level > 20 mmol/l on 
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<H1>Discussion 
These data examine in detail for the first time the diurnal character of interstitial glucose levels in an 
unselected group of women receiving dexamethasone in the context of paclitaxel/carboplatin 
chemotherapy for gynaecological cancer. Interestingly, we found that raised interstitial glucose was 
present at some point in almost all women (94%) in this cohort. This is in contrast to previous 
reports of glucocorticoid use, which reported an incidence of 9.4 to 50% depending on the 
population studied, glucocorticoid dose and duration, and clinical context [16–24]. One study of 
acute glucocorticoid use in a hospitalized population reported that > 50% of those receiving high-
dose glucocorticoids ( 40 mg prednisolone equivalents) exhibited at least one episode of 
hyperglycaemia [24]. Reasons for the comparatively high level of hyperglycaemia noted in this 
cohort are: (1) the use of CGM rather than pre- or post-meal blood glucose testing is likely to 
capture otherwise unobserved glucose excursions; (2) the glucocorticoid dose in our cohort was 
considerably higher than in previous studies (30 mg dexamethasone on day 1, 200 mg prednisolone 
equivalents vs. 40 mg prednisolone equivalents [24], given twice daily rather than as a once-daily 
morning dose); (3) women in our study had the combined effect of glucocorticoid exposure and the 
physiological stress of chemotherapeutic agents; and (4) this study measured interstitial glucose 
levels, whereas previous reports have typically examined whole blood glucose measurement. Given 
the possibility that hyperglycaemia may influence disease-free survival, this is an important 
observation. 
 
As with previous studies, we found that peak glucose levels were detected in the late afternoon in 
most cases [25]. We also demonstrated, however, that high glucose levels do occur throughout the 
night and that significant peaks in glucose could arise up to 03.00, before declining to fasting levels. 
This is likely due the combined effects of using glucocorticoids in the early part of the day to avoid 
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would advocate on the basis of this study that capillary blood glucose levels measured between 
15.00 and 17.00 and between 19.00 and 22.00 are most likely capture peak glucose and thus 
optimally estimate the severity of hyperglycaemia in this chemotherapy/dexamethasone regime. 
Our data also suggest that individuals on twice-daily dexamethasone may require long-acting basal 
insulin or twice-daily fixed mix insulin to maintain adequate glucose control as recommended in 
current guidance [14]. Further studies are required to compare these findings with diurnal glucose 
profiles in other chemotherapy treatments with different dexamethasone doses and intervals. 
Although CGM is not routinely used for glucose monitoring in this context, the advent of ‘flash’ 
glucose monitoring systems makes this an entirely feasible prospect for future cancer care. 
 
Interestingly, in this study, we identified that HbA1c level, although normal in all but one woman, was 
associated with both severity and duration of raised interstitial glucose. This is in contrast to other 
published works which have consistently indicated that BMI and age were the dominant predictors 
of dysglycaemia, as well as dose and duration of glucocorticoid therapy [17]. We speculate that this 
finding is due the immediate measurement of glucose levels after comparatively high-dose 
glucocorticoid rather than following protracted treatment of moderate dose glucocorticoid therapy, 
as observed previously [17]. HbA1c may be a more accurate reflection of insulin sensitivity and 
pancreatic β-cell function, which are immediately challenged by high-dose glucocorticoid exposure, 
whereas elevated BMI and increasing age may confer susceptibility to the obesogenic and 
dyslipidaemic effects of chronic supraphysiological glucocorticoid exposure. 
 
One woman in this study had pre-diabetes with an HbA1c of 44 mmol/mol (6.2%). This woman 
exhibited more severe and protracted raised interstitial glucose, with a peak glucose of 22.2 mmol/l; 
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of dexamethasone. Although this is a single case, it suggests that an HbA1c in the pre-diabetes range 
confers high risk of a significant prolonged hyperglycaemic state in people on this regimen. 
 
Further work is now warranted to determine whether maintenance of euglycaemia affects outcome 
in individuals with hyperglycaemia induced by chemotherapeutic regimes. It is important to note 
that what we have defined as raised interstitial glucose in this study (11.1 mmol/l) was chosen as it is 
a level women without diabetes would be unlikely to display without some level of physiological 
stress or pharmacological intervention. If indeed hyperglycaemia does independently effect 
outcome, the physiological level and duration at which this occur are unknown. Importantly, in vitro 
studies in which hyperglycaemia was detrimental to anti-mitotic treatment were conducted at 
significantly higher levels (25 mmol/l) [11]. 
 
To our knowledge, only one randomized control study of intensive glycaemic control during 
chemotherapy has been reported. Vu and colleagues examined the effect of intensive insulin 
therapy using a basal bolus regime, dietary advice and education vs. standard care in unselected 
individuals treated for haematological malignancy. Despite improved control, there was no 
improvement in outcome and secondary analysis suggested that high levels of exogenous insulin 
may be associated with early relapse [26]. By contrast, the insulin sensitizer metformin has been 
associated repeatedly with a reduced risk of multiple cancer types [27,28] and early prospective 
studies in ovarian cancer treatment are encouraging [29]. As such, there is clear need for a large 
prospective randomized trial on the routine use of other agents that prevent hyperinsulinemia as an 
adjunct to carboplatin/paclitaxel/dexamethasone chemotherapy and indeed many such trials are 
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In conclusion, raised interstitial glucose is present in almost all women undergoing this treatment 
regimen, and typically peaks within the 13.00–17.00 and 19.00–20.00 periods. Baseline HbA1c is 
associated with the severity and duration of glucose excursions. Further studies are awaited to 








Medtronic iPRO2™ devices were supplied by Medtronic (Northridge, CA, USA). Clinical assessments 
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FIGURE 1 Schematic of study design. On day 1, 20 mg of dexamethasone was given at 04.00 with a further 
10 mg at 10.00. On days 2–4, 4 mg dexamethasone was administered at 08.00 and 12.00. 
 
FIGURE 2 Boxplot with overlying jitter plot of peak glucose level observed in each participant on each study 
day. Dashed line indicates 11.1 mmol/l threshold. Each point represents one person. 
 
FIGURE 3 Boxplot with overlying jitter plot of time spent with a raised interstitial glucose (> 11.1  mmol/l) for 
each participant on each day of the study. Each point represents one person. 
 
FIGURE 4 Heat map visualization of glucose levels for all participants through the course of the study. Each row 
depicts glucose levels for one person. The participant with an HbA1c in the ‘pre-diabetes’ range (44 mmol/mol, 
6.2%) is identified by * on each day. Glucose levels: blue, < 11.1 mmol/mol; white, 11.1 mmol/mol; red, 
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Family history of 
diabetes 
Cancer diagnosis 
1 52.3 34 (5.2) 
26.
3 No No Stage III Grade 3 ovarian cancer 
3 69.2 35 (5.3) 
32.
1 No No 
Stage III C grade 3 serous papillary 
ovary cancer 
4 60.1 40 (5.8) 
23.
7 No 
Yes; nephew Type 1 
diabetes 
Relapsed serous papillary ovarian 
cancer 
5 65.2 35 (5.3) 
34.
3 No 
Yes; sister Type 2 
diabetes, niece Type 
1 diabetes Stage 1A clear cell ovarian carcinoma 
6 64.7 38 (5.6) 
27.
3 No No Stage III C serous papillary carcinoma 
7 74.2 38 (5.8) 
25.
1 No No Stage III C ovary cancer 
8 57.0 40 (5.8) 38 No No Relapsed ovarian cancer Stage IV 
9 70.0 39 (5.7) 28 No No 
Stage III C Grade 3 Serous papillary 
adenocarcinoma 
10 70.0 44 (6.2) 
30.
4 No No Relapsed ovarian cancer 
11 66.0 33 (5.2) 
21.
7 No No Clear cell adenocarcinoma 
12 46.7 35 (5.3) 40 No 
Yes; mother and 
father Type 2 
diabetes 
Stage 1 A High grade endometroid 
ovarian cancer 




Type 2 diabetes 
Stage III C High grade serous ovarian 
cancer 
14 55.8 41 (5.9) 
34.
2 No No 
Stage III C High grade serous ovarian 
cancer 
17* 55.4 33 (5.2) 
24.
8 No No 
Stage III C High grade serous ovarian 
cancer 
18 42.9 31 (5.0) 
22.
2 No No 
Stage 2 B Grade 2 endometroid 
adenocarcinoma 
19 50.7 39 (5.7) 
32.
3 No No Stage II C clear cell of the ovaries 
Mean 60.1 37.1 
29.
1 
   SD 8.8 3.4 5.4 
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